AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to incorporate the invention of T-cell engagers for the therapy of most cancers.
Underneath the deal, AbCellera (NASDAQ:ABCL) will lead discovery efforts, with AbbVie (NYSE:ABBV) retaining the appropriate to
